Cantor Fitzgerald restated their overweight rating on shares of LifeMD (NASDAQ:LFMD – Free Report) in a report released on Friday, Benzinga reports. Cantor Fitzgerald currently has a $15.00 target price on the stock.
Other equities analysts have also issued research reports about the company. B. Riley started coverage on LifeMD in a report on Friday, August 23rd. They set a buy rating and a $11.00 price objective on the stock. KeyCorp dropped their price target on LifeMD from $12.00 to $10.00 and set an overweight rating on the stock in a research note on Thursday, July 11th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of Buy and an average price target of $12.00.
Check Out Our Latest Research Report on LifeMD
LifeMD Price Performance
LifeMD (NASDAQ:LFMD – Get Free Report) last issued its quarterly earnings results on Wednesday, August 7th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.06). The company had revenue of $50.66 million for the quarter, compared to the consensus estimate of $48.47 million. During the same period in the prior year, the company earned ($0.23) EPS. On average, research analysts forecast that LifeMD will post -0.49 earnings per share for the current fiscal year.
Institutional Investors Weigh In On LifeMD
Hedge funds have recently modified their holdings of the company. Quest Partners LLC purchased a new position in shares of LifeMD during the 2nd quarter worth about $31,000. Los Angeles Capital Management LLC acquired a new position in shares of LifeMD in the 2nd quarter valued at $88,000. EntryPoint Capital LLC acquired a new position in shares of LifeMD in the 1st quarter valued at $89,000. The Manufacturers Life Insurance Company purchased a new stake in shares of LifeMD during the 2nd quarter valued at $93,000. Finally, XTX Topco Ltd purchased a new position in shares of LifeMD in the 2nd quarter worth $94,000. 35.52% of the stock is owned by institutional investors and hedge funds.
LifeMD Company Profile
LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.
Featured Articles
- Five stocks we like better than LifeMD
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- The Average 401k Balance by Age Explained
- What is the S&P 500 and How It is Distinct from Other Indexes
- 3 Uranium Stocks To Gain as Microsoft Goes Nuclear to Power AI
- What is a Secondary Public Offering? What Investors Need to Know
- Biotech Boom Ahead? Key Stocks and ETFs to Watch Now
Receive News & Ratings for LifeMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LifeMD and related companies with MarketBeat.com's FREE daily email newsletter.